NASDAQ:RANI Rani Therapeutics Q1 2026 Earnings Report $1.11 +0.06 (+5.71%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.63%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Rani Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.06Beat/MissN/AOne Year Ago EPSN/ARani Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.13 millionBeat/MissN/AYoY Revenue GrowthN/ARani Therapeutics Announcement DetailsQuarterQ1 2026Date5/15/2026TimeBefore Market OpensConference Call DateThursday, May 21, 2026Conference Call Time4:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Rani Therapeutics Earnings HeadlinesRani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor ConferenceMay 12 at 4:05 PM | globenewswire.comRani Therapeutics (RANI) Expected to Announce Earnings on WednesdayMay 11, 2026 | americanbankingnews.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today. | Brownstone Research (Ad)This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last YearMay 9, 2026 | finance.yahoo.comRani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14April 9, 2026 | msn.comRani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical StrategyApril 9, 2026 | globenewswire.comSee More Rani Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rani Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rani Therapeutics and other key companies, straight to your email. Email Address About Rani TherapeuticsRani Therapeutics (NASDAQ:RANI) is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company’s proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones. Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery. In addition to its insulin candidate, the company is exploring oral formulations of GLP-1 receptor agonists and other therapeutic proteins. Rani has secured investigational new drug (IND) approvals and completed initial safety and pharmacokinetic assessments in humans, positioning its RaniPill platform for broader application across multiple chronic disease areas. Headquartered in San Jose, California, Rani Therapeutics leverages collaborations with research institutions and industry partners to streamline development and manufacturing. While still in the clinical stages, the company is preparing for pivotal trials and regulatory interactions to support future commercialization. Rani’s management team combines expertise from pharmaceutical development, medical device engineering and regulatory affairs, underscoring its commitment to transforming biologic drug delivery and expanding patient access globally.View Rani Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles YETI Rallies After Earnings Beat and Raised OutlookCisco’s Vertical Rally May Still Be in the Early InningsHow the 3 Leading Quantum Firms Stack Up After Q1 EarningsNebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunAmazon vs. Alibaba: One Is Clearly The Better Value Play right NowD-Wave Earnings Looked Weak, But Investors May Be Missing This Upcoming Earnings Baidu (5/18/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
